Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

IO-202

Alternative Names: io-202, io 202, io202
Latest Update: 2025-02-27
Latest Update Note: News Article

Product Description

IO-202 is a first-in-class monoclonal antibody that antagonizes LILRB4 with high binding affinity and specificity. It has broad potential in blood cancers and solid tumors and presents an opportunity to become a pipeline in a product. (Sourced from: https://www.immune-onc.com/io-202)

Mechanisms of Action: LILRB4 Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation:
Fast Track - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia
Orphan Drug - Acute Myeloid Leukemia
Orphan Drug - Chronic Leukemia|Chronic Myelomonocytic Leukemia|Leukemia *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Immune-Onc Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: BeiGene

Clinical Description

Map of Global Clinical Trials for IO-202

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
IO-202-CL-001

P1

Completed

Chronic Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia

2025-01-31

IO-202-CL-002

P1

Completed

Oncology Solid Tumor Unspecified

2024-03-29

25%

Recent News Events

Date

Type

Title

02/27/2025

News Article

 Immune-Onc Therapeutics Announces First Patient Dosed with IO-108 in a Randomized Global Phase 1b/2 Study of First-Line Treatment of Advanced Liver Cancer in Clinical Collaboration with Roche

12/09/2024

News Article

 Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting

11/20/2024

News Article

 The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment

06/14/2024

News Article

 Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions